Data back IMI's efforts in colorectal, lung and breast cancers
This article was originally published in Clinica
Canada's IMI International Medical Innovations says that its mucus-based screening tests for lung, colorectal and breast cancers are showing "significant" promise in clinical trials.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.